WEDNESDAY, JUNE 30 | EDT

Industry Leaders Plenary Discussion

8:00 am Morning Coffee

8:35 am Chair’s Opening Remarks

8:45 am Industry Leaders Panel Discussion

Synopsis

• What have been the most exciting developments within the past 12 months?
• What does the path of approval and the commercialization of these products look like?
• If C.difficle and consortia-based therapeutics was the low-hanging fruit, what is the next area of microbiome research?
• What are the biggest challenges the field will face over the next 3 years?

9:45 am

Lightning Discussion 1: Biggest Lessons From the Past 12 Months

Synopsis

Following on from our Industry Leader’s Discussion, where our expert faculty would have touched on the biggest challenges they
have recently faced, this is your opportunity to join your peers for three, five minute quick fire discussion to share your thoughts on:
• What has been your biggest challenge in the last year?
• What challenges are you expecting to arise within the next 3 years?

10:00 am Microbiome Endgame: Preparing Microbiome Products for Regulatory Requirements Through cGMP Program Design

  • Yvonne Nyavor Principal Scientist, Microbiome, Boston Analytical

Synopsis

• Due to the novel nature of most microbiome based therapeutics, the guidance available from regulatory agencies has relied on industry and regulatory expertise
• An overview of current regulatory testing for microbiome based therapeutics, what purpose these tests serve, and a discussion on what future regulatory testing might include
• How to best position your products in the current regulatory testing framework

10:30 am Developing Bacterial Consortia Therapeutics for Infectious and Inflammatory Disease Targets

Synopsis

• Providing an update on Seres’ clinical and pre-clinical pipeline
• Discussing candidates including SER-109, which in a Phase 3 Clinical Trial led to a statistically significant reduction in C.difficile recurrence

11:00 am Meeting the Maturing Supply Needs of the Microbiome Sector

Synopsis

• Assessment of the growth in the microbiome space
• Solutions to meet the process development and clinical needs of the sector
• Investing to support the commercial supply needs of the sector

11:30 am

Lightning Networking 2: What are you hoping to achieve from this meeting?

Synopsis

Another opportunity for three, five minute discussions focussing on the next two days of content:
• What is the one thing that you are looking at getting out of this meeting?
• What services would you be most learn more about?

TRACK A: UNDERSTANDING MICROBIOME FUNCTIONALITY & PRE-CLINICAL DEVELOPMENT

Understanding Mechanisms & Functions of Live Biotherapeutics

12:00 pm Preclinical Solutions for Microbiome Investigation in Pathological Situation & Drug Development

  • Sylvie Maubant Head of Study & Research Unit – In vivo Sciences Department, Oncodesign

Synopsis

• Microbiome-based therapeutics: which models, which assays?
• Drug-microbiome interactions: a requirement for efficacy and safety assessment?
• Case studies for oncology and inflammatory diseases

12:10 pm Health Through Diversity: Designing Microbial Consortia for Lasting Benefit

Synopsis

• General introduction of Federation Bio platforms
• Discussion of the advantage of a microbial community approach over traditional therapeutic modalities
• Results of our lead program in secondary hyperoxaluria, including in vivo study data

12:40 pm Examining the Role of the Microbiome in Metabolic Disease

Synopsis

• Discussing how to establish causation, rather than correlation with your research
• Delve into understanding the mechanisms linking the microbiome to phenotype
• Discuss whether FMT can be used as an effective treatment?

TRACK B: CLINICAL TRANSLATION & MANUFACTURING OF MICROBIOME THERAPEUTICS

Leveraging Lessons from the Clinic to Guide Future Success

12:00 pm Leveraging Experience & Expertise to Support the Development & Manufacturing of Microbiome Therapeutic Products

Synopsis

• Utilization of Single Use Equipment in the LBP Process Flow
• Novel Dosage Forms
• Innovative Product Delivery Platforms
• Microbiome Derived Protein Products

12:10 pm Forging a New Frontier – Driving Clinical Development of RBX2660, a Novel Live Biotherapeutic

  • Paul Plumb Director, Clinical Development, Rebiotix

Synopsis

• Clinical development challenging; even more so with the introduction of a novel approach to treatments via a live biotherapeutic
• Rebiotix, a Ferring Company, was the first company to approach the US FDA with a microbiota-based formulation to evaluated as a standardized, stabilized therapeutic option for recurrent C. difficile infection
• These learnings and personal connections have helped us build the leading clinical development program in the world. To date, the company has executed 6 clinical trials with over 900 patients for its leading investigational therapeutic, RBX2660

12:40 pm Protecting and Preserving the Intestinal Microbiota From Antibiotic-Induced Dysbiosis With dav132, a Novel Colon-Targeted Adsorbent: An Effective and Safe Solution for Cancer Patients

Synopsis

• DAV132, a first-in-class chemical product that sequesters and inactivates antibiotics circulating in the colon is able to preserve patients’ intestinal microbiota without impacting antibiotics’ plasma pharmacokinetics and efficacy, in a Phase 2 clinical study
• The understanding of DAV132 mode of action in humans is reinforced by a series of clinical studies conducted in healthy subjects and including microbiota analyses
• Additional work showing the importance of protecting the microbiota of cancer patients treated with immune checkpoint inhibitors will also be presented

TRACK C: MICROBIOME BIOMARKERS, PATIENT STRATIFICATION & DIAGNOSTICS

Exploring Approaches to Biomarker Discovery

12:00 pm From Microbiome Research into Clinical Practice

Synopsis

• Microbiome research has increased drastically in recent years, focusing on causation and mechanism leading to health and disease conditions
• Microbiome research is now incorporating different *omics* approaches to answer those fundamental questions
•The methods vary widely between different studies and labs and the results are often not comparable
•Standardization is crucial for translating the scientific finding into clinical practice

12:30 pm Panel Discussion – What Are We Looking for in a Microbiome Biomarker?

Synopsis

•Are we striving for a universally accepted biomarker? Is this achievable?
• Do we look for a marker of health, or a marker of disease?
•What is the FDA guidelines for microbiome-based biomarkers?
• How can biomarkers be used to intervene in health before disease sets in?

1:10pm Lunch / Demo Area

Synopsis

Use this break in proceedings to make some lunch and coffee and head across to the Demo Area to connect with our Event Partners

2:00 pm Harness the Power of Metabolomics to Advance Microbiome Drug Development

  • Brian Ingram Director, Discovery and Translational Sciences, Metabolon

Synopsis

• Find out how metabolomics can provide a functional readout of the microbiome which can be used to complement other approaches such as genomics and proteomics and provide a deeper understanding of host-microbiome interactions and how these are impacted by disease and novel therapeutics
• Discover how the incorporation of metabolomics into drug discovery programs can assist in understanding the mechanism of action, safety, and efficacy of new and novel treatments as well as aiding in aspects important for consistent clinical outcomes such as patient stratification
• Learn about several metabolomic solutions, ranging from broad global metabolomic profiling to targeted analysis of specific microbial analytes, that can provide actionable insights to advance drug development
• Gain unique and valuable insights key to understanding the microbiome’s role in several therapeutic areas using metabolomics through discussion of select case studies

2:30 pm Live Biotherapeutics to Treat and Prevent Chronic Lung Infections

Synopsis

• LBPs as anti-infectives administered direct to the lungs offer many advantages over small molecules
• Aeruguard: review of a LBP for Psuedomonas & Staph lung infections including effects on the gut
• Mybacguard: review of a LBP for Non-tuberculous Mycobacterial (NTM) lung infections

Advancing Pre-Clinical Model Development to Improve Translatability

3:00 pm Microbiome Considerations in Preclinical Animal Modeling

  • Caitlin SL Parello Senior Scientist II, Associate Director of in vitro Services, Biomodels

Synopsis

•Introduction on the role of the microbiome in various human disease states
• Discussion of strategies for assessing microbiome effects in disease models
•Examples of microbiome influence in disease modeling

3:10 pm Pre-Clinical Animal Models to Understand the Influence of the Microbiome on the Host-Immune System

  • Gokul Swaminathan Associate Principal Scientist, Investigational Biology, Merck Exploratory Science

Synopsis

• Evaluation of the influence of antibiotic treatment on vaccine outcome in murine and non-human primate models
• Use of germ-free murine models to understand mechanisms of microbial entities that can influence the host immune system
• Characterizing global immune cell pathways modulated in murine models of dysbiosis

3:40 pm Afternoon Virtual Networking & Coffee

2:00 pm A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes

Synopsis

•Utilizing data from human microbiota transplantation studies and machine learning to develop novel microbiome therapeutics and retire risk early
•Applying a Human-First Discovery approach to the development of microbiome therapeutics for a diverse range of conditions, such as inflammatory bowel disease and autism spectrum disorder

2:30 pm Designing & Executing Microbiome-Therapeutic Clinical Trials

  • Stacy Kahn Attending Gastroenterologis , Boston Children's Hospital

Synopsis

•How do you design an FMT clinical trial?
•What considerations should be made when executing a trial?

3:00 pm Talk Details TBC

3:10 pm Afternoon Virtual Networking & Coffee

2:00 pm Live Bacterial Therapeutic and Biomarker From a Clinical Microbiome Signature of Checkpoint Inhibitor Drug Response in Cancer

Synopsis

• Precision microbiome profiling plus MELRESIST study led to identification of a single clinical signature predictive of checkpoint inhibitor response across multiple melanoma and lung cancer studies
• Live bacterial therapeutic MB097, comprising 9 bacteria from this clinical signature, demonstrates efficacy in mouse models
• MB097 constituent bacteria demonstrate multiple immuno-stimulatory mechanisms in primary human immune cell assays in vitro
• MB097 is in preclinical development progressing to the clinic for treatment of patients not responding to anti-PD1s

2:30 pm Xmarker – A Novel Platform to Discover Microbiome Based Biomarkers

Synopsis

• A high resolution accurate non-referenced based approached to analyse metagenomic data
• Rapid discovery enabled through a cloud based platfrom within a few months
• Identification of metagenomic based signatures for IBD and liver diseases

3:00 pm The Strategic Role of Microbiome Biomarkers in Diagnostics & Therapeutics

Synopsis

• Microbiome-derived biomarkers are unique as they can be altered by external intervention, they are
modulatable
•Biomarker and therapeutic development are linked through the microbiome
•Selecting for or against certain biomarkers lead to separate stratification and therapeutic strategies

3:30 pm Afternoon Virtual Networking & Coffee

Leveraging Small Molecules to Modulate the Microbiome

4:30 pm Synthetic Glycans to Optimize Microbiome Composition & Function for Therapeutic Outcomes

Synopsis

• Synthetic glycans as targeted modulators of microbiome composition and metabolic output
• Human centric discovery through ex-vivo screening and non-clinical studies
• Translational clinical studies

5:00 pm Expanding the Drug Discovery Space With Predicted Metabolite-Target Interactions

Synopsis

• Drug discovery requires to go beyond statistical association of metabolites with disease state
• Mullti’omics cohorts and publicly available data allow computational approaches to infer novel drug targets
• This study uncovered more than 900 metabolite host receptor pairs that can be useful to design treatments for inflammatory bowel disease (after experimental validation)

5:30 pm Inventing Medicine by Accessing the Microbiome Dark Matter

Synopsis

• The “dark matter” of human microbiome is highly valuable for drug discovery, yet remains largely inaccessible
• The methods and challenges in unlocking the microbiome dark matter
• DeepBiome’s platform and its progress

4:30 pm Presentation Reserved for Event Partner

Synopsis

For more information, contact; partner@microbiome-movement.com

5:00 pm Presentation Reserved

5:30 pm Oral Microbiome Breakout Session

Synopsis

•Provide an overview of the oral microbiome
•Give an insight into BrickBuilt Therapeutics Inc.
• Discuss future directions and possibilities involving the oral microbiome

Application of Biomarkers in the Discovery of New Drugs and in Clinical Development

4:00 pm Biomarkers to Evaluate Microbiome Therapeutic Drug Pharmacokinetics & Pharmacodynamics

  • Chris Ford Senior Director, Computational Microbiome Scientist, Seres Therapeutics

Synopsis

• Harnessing microbiome biomarkers to understand PK/PD of a microbiome therapeutic
• Using this information to inform the drug development pipeline

4:30 pm Biomarker Assay Development Considerations for Microbiome Therapies

Synopsis

• Microbiome drugs necessitate thinking about PK and PD in non-traditional ways
• Dynamics of microbial engraftment and timing of measurement are important for understanding PK
• Demonstrating the expected functionality of constituent microbes is an additional PD considerations in addition to quantifying host effects

5:30 pm End of Track C

6:00 pm Closing Remarks – Day One

6:05 pm End of Day One